Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Shire
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02350816CT.gov An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093. | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mucopolysaccharidosis Type 3
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hgt-1410 (this asset) | Shire | P2 | CCC · 53 |
| Amidase, Sulfoglucosamine Sulf- | Shire | P2 | B |
| Dna (Synthetic Adeno-Associated Virus 9 Vector Scaav9.U1A.Hsgsh Human N-Sulfoglucosamine Sulfohydrolase-Specifying) | Ultragenyx Pharmaceutical Inc | P2/3 | B |
| Ambroxol | Ozlem Goker-Alpan | P2/3 | B |
| Alemtuzumab | Masonic Cancer Center, University of Minnesota | P2 | B |
| Hydroxyurea | Masonic Cancer Center, University of Minnesota | P2 | B |
| Clofarabine | Masonic Cancer Center, University of Minnesota | P2 | B |
| Melphalan | Masonic Cancer Center, University of Minnesota | P2 | B |
| Duoc-01 | Joanne Kurtzberg, MD | P1 | CC |
Other indications for Hgt-1410
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mucopolysaccharidosis | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Amidase, Sulfoglucosamine Sulf-ShireB
- Dna (Synthetic Adeno-Associated Virus 9 Vector Scaav9.U1A.Hsgsh Human N-Sulfoglucosamine Sulfohydrolase-Specifying)Ultragenyx Pharmaceutical IncB
- AmbroxolOzlem Goker-AlpanB
- AlemtuzumabMasonic Cancer Center, University of MinnesotaB
- HydroxyureaMasonic Cancer Center, University of MinnesotaB
Citation
Floatz Terminal. Hgt-1410 in Mucopolysaccharidosis Type 3. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hgt-1410-mucopolysaccharidosis-type-3
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →